دورية أكاديمية
أعرض في EDS

Plasma Metabolite Profiling Identifies Nondiabetic Chronic Pancreatitis Patients With Metabolic Alterations Progressing to Prediabetes Before HbA1c.

التفاصيل البيبلوغرافية
العنوان: Plasma Metabolite Profiling Identifies Nondiabetic Chronic Pancreatitis Patients With Metabolic Alterations Progressing to Prediabetes Before HbA1c.
المؤلفون: Ketavarapu V; Translational Research Center, Asian Healthcare Foundation, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Addipilli R; Centre for Mass Spectrometry, Department of Analytical & Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India., Ragi N; Centre for Mass Spectrometry, Department of Analytical & Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India., Pallerla P; Centre for Mass Spectrometry, Department of Analytical & Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India., Simhadri V; Translational Research Center, Asian Healthcare Foundation, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Manne S; Translational Research Center, Asian Healthcare Foundation, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Sannapaneni K; Translational Research Center, Asian Healthcare Foundation, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Aslam M; Asian Institute of Gastroenterology, Somajiguda, Hyderabad, Telangana, India., Talukadar R; AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Ch VD; Department of Biochemistry, University College of Science, Osmania University, Hyderabad, Telangana, India., Gv R; AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Amanchy R; Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India., Reddy DN; AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India., Sripadi P; Centre for Mass Spectrometry, Department of Analytical & Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India., Sasikala M; Translational Research Center, Asian Healthcare Foundation, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana, India.
المصدر: Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2024 Jun 01; Vol. 15 (6), pp. e1. Date of Electronic Publication: 2024 Jun 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101532142 Publication Model: Electronic Cited Medium: Internet ISSN: 2155-384X (Electronic) Linking ISSN: 2155384X NLM ISO Abbreviation: Clin Transl Gastroenterol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2019-> : [Philadelphia, PA] : Wolters Kluwer Health
Original Publication: New York, NY : Nature Pub. Group
مواضيع طبية MeSH: Pancreatitis, Chronic*/blood , Pancreatitis, Chronic*/diagnosis , Prediabetic State*/blood , Prediabetic State*/diagnosis , Biomarkers*/blood , Glycated Hemoglobin*/analysis , Glycated Hemoglobin*/metabolism , Metabolomics*/methods, Humans ; Male ; Female ; Middle Aged ; Adult ; Disease Progression ; Lysophospholipids/blood ; Lysophospholipids/metabolism ; Carnitine/blood ; Carnitine/analogs & derivatives ; Tandem Mass Spectrometry ; Case-Control Studies ; Glucose Tolerance Test ; Ceramides/blood ; Blood Glucose/analysis ; Blood Glucose/metabolism ; Aged ; Chromatography, Liquid ; Pancreas/pathology ; Pancreas/metabolism ; Metabolome ; Lysophosphatidylcholines/blood
مستخلص: Introduction: Diabetes (T3cDM) secondary to chronic pancreatitis (CP) arises due to endocrine dysfunction and metabolic dysregulations. Currently, diagnostic tests are not available to identify patients who may progress from normoglycemia to hyperglycemia in CP. We conducted plasma metabolomic profiling to diagnose glycemic alterations early in the course of disease.
Methods: Liquid chromatography-tandem mass spectrometry was used to generate untargeted, targeted plasma metabolomic profiles in patients with CP, controls (n = 445) following TRIPOD guidelines. Patients were stratified based on glucose tolerance tests following ADA guidelines. Multivariate analysis was performed using partial least squares discriminant analysis to assess discriminatory ability of metabolites among stratified groups. COMBIROC and logistic regression were used to derive biomarker signatures. AI-ML tool (Rapidminer) was used to verify these preliminary results.
Results: Ceramide, lysophosphatidylethanolamine, phosphatidylcholine, lysophosphatidic acid (LPA), phosphatidylethanolamine, carnitine, and lysophosphatidylcholine discriminated T3cDM CP patients from healthy controls with AUC 93% (95% CI 0.81-0.98, P < 0.0001), and integration with pancreatic morphology improved AUC to 100% (95% CI 0.93-1.00, P < 0.0001). LPA, phosphatidylinositol, and ceramide discriminated nondiabetic CP with glycemic alterations (pre-diabetic CP); AUC 66% (95% CI 0.55-0.76, P = 0.1), and integration enhanced AUC to 74% (95% CI 0.55-0.88, P = 0.86). T3cDM was distinguished from prediabetic by LPA, phosphatidylinositol, and sphinganine (AUC 70%; 95% CI 0.54-0.83, P = 0.08), and integration improved AUC to 83% (95% CI 0.68-0.93, P = 0.05). CombiROC cutoff identified 75% and 78% prediabetes in validation 1 and 2 cohorts. Random forest algorithm assessed performance of integrated panel demonstrating AUC of 72% in predicting glycemic alterations.
Discussion: We report for the first time that a panel of metabolites integrated with pancreatic morphology detects glycemia progression before HbA1c in patients with CP.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
References: Biochim Biophys Acta. 2008 Sep;1781(9):513-8. (PMID: 18621144)
Eur Urol. 2015 Jun;67(6):1142-1151. (PMID: 25572824)
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396. (PMID: 34019663)
Am J Gastroenterol. 2017 Sep;112(9):1457-1465. (PMID: 28741615)
Technol Health Care. 2024;32(2):605-613. (PMID: 37522229)
Pancreas. 2018 Nov/Dec;47(10):1229-1238. (PMID: 30325862)
PLoS One. 2014 Sep 09;9(9):e105343. (PMID: 25202985)
Dig Dis Sci. 2022 Feb;67(2):708-715. (PMID: 33630214)
Diabetes Care. 2023 Jan 1;46(1):46-55. (PMID: 36382801)
Pancreatology. 2021 Jan;21(1):15-20. (PMID: 33257226)
Cell Physiol Biochem. 2015;35(4):1253-75. (PMID: 25721445)
Mol Cell Proteomics. 2015 Jun;14(6):1684-95. (PMID: 25787789)
Sci Rep. 2017 Mar 30;7:45477. (PMID: 28358118)
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):226-237. (PMID: 28404095)
Cell Physiol Biochem. 2017;43(2):445-456. (PMID: 28922661)
Gut. 2018 Jan;67(1):128-137. (PMID: 28108468)
Biomol Ther (Seoul). 2015 Jan;23(1):1-11. (PMID: 25593637)
J Lipid Res. 2014 Jul;55(7):1192-214. (PMID: 24643338)
Drugs. 2023 Aug;83(12):1077-1090. (PMID: 37410209)
Gut. 2021 Nov;70(11):2150-2158. (PMID: 33541865)
Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489. (PMID: 37301218)
Pancreas. 2016 Apr;45(4):565-71. (PMID: 26918872)
Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10. (PMID: 18953024)
Comput Methods Programs Biomed. 1995 Dec;48(3):257-62. (PMID: 8925653)
Anal Bioanal Chem. 2014 Nov;406(28):7137-48. (PMID: 25230597)
معلومات مُعتمدة: SERB: CRG2019002570 Science and Engineering Research Board
المشرفين على المادة: 0 (Biomarkers)
0 (Glycated Hemoglobin)
0 (Lysophospholipids)
S7UI8SM58A (Carnitine)
0 (hemoglobin A1c protein, human)
PG6M3969SG (lysophosphatidic acid)
0 (Ceramides)
0 (Blood Glucose)
0 (Lysophosphatidylcholines)
تواريخ الأحداث: Date Created: 20240425 Date Completed: 20240625 Latest Revision: 20240712
رمز التحديث: 20240712
مُعرف محوري في PubMed: PMC11196079
DOI: 10.14309/ctg.0000000000000704
PMID: 38661171
قاعدة البيانات: MEDLINE
الوصف
تدمد:2155-384X
DOI:10.14309/ctg.0000000000000704